Clobazam

Generic Name
Clobazam
Brand Names
Onfi, Sympazan
Drug Type
Small Molecule
Chemical Formula
C16H13ClN2O2
CAS Number
22316-47-8
Unique Ingredient Identifier
2MRO291B4U
Background

Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a b...

Indication

Clobazam is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Associated Conditions
Anxiety, Catamenial Epilepsy, Refractory Status Epilepticus, Seizures, Status Epilepticus
Associated Therapies
-
Clinical Trials
Related News

The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children

First Posted Date
2023-01-26
Last Posted Date
2023-01-26
Lead Sponsor
Dr Cipto Mangunkusumo General Hospital
Target Recruit Count
100
Registration Number
NCT05697614
Locations
🇮🇩

Cipto Mangunkusumo Hospital, Jakarta Pusat, Jakarta, Indonesia

🇮🇩

Harapan Kita Hospital, Jakarta, Indonesia

🇮🇩

Fatmawati Hospital, Jakarta, Indonesia

GABA Pathways in Autism Spectrum Disorder (ASD)

First Posted Date
2018-09-19
Last Posted Date
2023-09-26
Lead Sponsor
King's College London
Target Recruit Count
50
Registration Number
NCT03678129
Locations
🇬🇧

King's College London, London, United Kingdom

Use of Clobazam for Epilepsy and Anxiety

Phase 4
Completed
Conditions
Epilepsy
Anxiety
Interventions
Drug: Clobazam
First Posted Date
2017-12-13
Last Posted Date
2021-03-04
Lead Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Target Recruit Count
20
Registration Number
NCT03371836
Locations
🇺🇸

Kennedy Krieger Institute, Baltimore, Maryland, United States

Population Pharmacokinetics of Antiepileptic in Pediatrics

First Posted Date
2017-06-22
Last Posted Date
2024-10-30
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
1000
Registration Number
NCT03196466
Locations
🇫🇷

AP-HP Cochin, Paris, France

Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy

Phase 4
Conditions
Epilepsy
Interventions
Drug: Clobazam
First Posted Date
2016-04-04
Last Posted Date
2017-03-23
Lead Sponsor
Pavel Klein
Target Recruit Count
20
Registration Number
NCT02726919
Locations
🇺🇸

MidAtlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States

An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Phase 2
Completed
Conditions
Epilepsy
Interventions
Drug: GWP42003-P
Drug: Clobazam
First Posted Date
2015-10-01
Last Posted Date
2022-09-28
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
18
Registration Number
NCT02564952

A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

First Posted Date
2015-10-01
Last Posted Date
2022-09-28
Lead Sponsor
Jazz Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT02565108

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Phase 3
Terminated
Conditions
Dravet Syndrome
Interventions
Drug: Clobazam
First Posted Date
2014-07-11
Last Posted Date
2017-03-27
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
3
Registration Number
NCT02187809
Locations
🇺🇸

US010, Los Angeles, California, United States

🇺🇸

US003, Rochester, Minnesota, United States

🇺🇸

US0011, Dallas, Texas, United States

and more 6 locations

Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

Phase 3
Withdrawn
Conditions
Dravet Syndrome
Interventions
Drug: Clobazam
Drug: Placebo
First Posted Date
2014-06-25
Last Posted Date
2015-09-24
Lead Sponsor
H. Lundbeck A/S
Registration Number
NCT02174094
Locations
🇺🇸

US003, Rochester, Minnesota, United States

🇺🇸

US006, Dallas,, Texas, United States

🇺🇸

US010, Los Angeles, California, United States

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy